Earnings Call Summary | AxoGen(AXGN.US) Q4 2023 Earnings Conference
Earnings Call Summary | AxoGen(AXGN.US) Q4 2023 Earnings Conference
The following is a summary of the AxoGen, Inc. (AXGN) Q4 2023 Earnings Call Transcript:
以下是 AxoGen, Inc. (AXGN) 2023年第四季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
AxoGen reported a full year 2023 revenue of $159 million, up 14.7% from the previous year and Q4 2023 revenue of $42.9 million, up 18.7% from Q4 2022.
Gross margin for the quarter was 78.7%, a decrease from 83% in Q4 2022 due to costs associated with starting tissue processing at the new facility.
Net loss for Q4 2023 was $3.9 million or $0.09 per share, a reduction from a net loss of $5.4 million or $0.13 in Q4 2022.
AxoGen报告称，2023年全年收入为1.59亿美元，比上年增长14.7％，2023年第四季度收入为4,290万美元，较2022年第四季度增长18.7％。
该季度的毛利率为78.7％，低于2022年第四季度的83％，这是由于与在新工厂开始组织加工相关的成本所致。
2023年第四季度的净亏损为390万美元，合每股亏损0.09美元，低于2022年第四季度的540万美元净亏损或0.13美元。
Business Progress:
业务进展：
The company made significant strides in surgeon adoption of AxoGuard HA+ and anticipates expanded adoption of nerve protection products.
AxoGen plans to launch Avive+ Soft Tissue Matrix in Q2 2024.
The new processing facility in Dayton, Ohio, is fully operational and positioned to support long-term growth.
FDA filing for BLA anticipated to be completed in Q3 of 2024, with potential approval in mid-2025.
该公司在外科医生采用AxoGuard HA+方面取得了长足的进步，并预计神经保护产品的采用范围将扩大。
AxoGen计划在2024年第二季度推出Avive+软组织矩阵。
位于俄亥俄州代顿的新加工设施已全面投入运营，有望支持长期增长。
美国食品药品管理局对BLA的申请预计将于2024年第三季度完成，并可能在2025年中期获得批准。
More details: AxoGen IR
更多详情： axoGen IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。无法完全保证内容的准确性。欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。